Japan cancer biomarkers market is growing at a CAGR of around 11.9% during the forecast period. Japan market for biomarkers is expected to witness positive growth during forecast period. The mortality rate in Japan due to cancer is increasing day by day. The reason for mortalities due to cancer tobacco smoking. The increasing prevalence of cancer holds a promising market for biomarkers in Japan for the treatment of cancers. In 2017, there were around 1.1 million cases of cancer were registered in which 149,500 cases were of colon cancer followed by 132,800 cases of stomach cancer and 128,700 cases of lung cancer.
To Request a Sample of our Report on Japan Cancer Biomarker Market: https://www.omrglobal.com/request-sample/japan-cancer-biomarker-market
Further, the mortality due to cancer in Japan is estimated to around 0.37 million in 2017, which is also affecting the Japan cancer biomarker market growth. According to the Tsugane’s contribution to cancer research, the population attributable fraction (PAF) of tobacco smoking to cancer was 24%, infection was 22%, alcohol drinking was 6%, and over-intake of salt was 1.4%. The causes of the other 50% of cancer death were not sufficiently clarified. Also studied the PAF for cancer incidence and found that it is almost the same as that for cancer death.
In June 2017, Immunovia was granted a patent for biomarker signature for pancreatic cancer diagnosis. This was done for the success of IMMray PanCan-d test in Japan which is a commercial market for Immunovia. Safeguard R&D investment in such novel diagnostic tests Effective patent protection is vital in order. Additionally, in August 2017, Biomarker Strategies received two patent approvals, one for Snap Path and other for PathMAP technologies. Japan is in need to develop more targeted disease detection and treatments for a rapidly growing patient population, augmenting the market for Japan cancer biomarkers.
(Get 15% Discount on Buying this Report)
A full Report of Japan Cancer Biomarker Market is Available @ https://www.omrglobal.com/industry-reports/japan-cancer-biomarker-market
Japan Cancer Biomarker Market Segmentation
By Biomarker Type
- Genetic Biomarker
- Protein Biomarker
By Cancer Type
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Other
By Applications
- Drug Discovery and Development
- Diagnosis
- Risk Assessment
- Prognostics
By Profiling Technology
- Omics Technology
- Immunoassays
- Cytogenetics
- Bioinformatics
Company Profiles
- Abbott laboratories Inc.
- Astellas Pharma Inc.
- Becton, Dickson and Co.
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- F. Hoffmann-La Roche Ltd.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc.
- QIAGEN GmbH
- Thermo Fisher Scientific Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
